Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus CABOMETYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus CABOMETYX.
BOSUTINIB MONOHYDRATE vs CABOMETYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor. It inhibits the BCR-ABL kinase, which is constitutively active in chronic myeloid leukemia (CML), and also inhibits Src family kinases. It has minimal inhibitory activity against c-KIT and PDGFR.
Cabozantinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, KIT, and FLT3. It inhibits tumor growth, angiogenesis, and metastasis by blocking these pathways.
400 mg orally once daily with food.
60 mg orally once daily for the first 21 days of a 21-day cycle, with or without food, for renal cell carcinoma; for hepatocellular carcinoma, 60 mg orally once daily.
None Documented
None Documented
22.5 hours; supports once-daily dosing, with steady-state achieved by day 8.
Terminal half-life approximately 99 hours (range 80–120 h). Supports once-daily dosing with steady-state achieved within 15 days.
Primarily fecal (91%, as unchanged drug and metabolites) with renal excretion accounting for <3%.
Primarily fecal (54%) with minimal renal excretion (27% unchanged drug; <10% as metabolites). Biliary excretion contributes to fecal elimination.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor